share_log

Recursion Pharmaceuticals | DEF 14A: Definitive information statements

Recursion Pharmaceuticals | DEF 14A: Definitive information statements

Recursion Pharmaceuticals | DEF 14A：股东委托书决议
美股SEC公告 ·  04/23 17:21

Moomoo AI 已提取核心信息

Recursion Pharmaceuticals, Inc. (Recursion) filed its definitive proxy statement with the SEC, detailing its upcoming Annual Meeting of Stockholders to be held virtually on June 3, 2024. The proxy statement includes proposals for the election of three Class III directors, Blake Borgeson, R. Martin Chavez, and Dean Y. Li, whose terms are set to expire at the meeting. The statement also addresses executive compensation, with a recommendation for stockholders to approve the compensation of Named Executive Officers. The report highlights key achievements in 2023, such as clinical program advancements, significant partnerships, and the development of the Recursion OS platform. Additionally, the proxy statement outlines the company's executive compensation philosophy, emphasizing a pay-for-performance culture and alignment with stockholder interests. The company's financial performance, including a net loss for the year, is also discussed. The proxy statement includes information on the ownership of Recursion's common stock by certain beneficial owners and management, as well as potential payments upon termination or change in control for executive officers.
Recursion Pharmaceuticals, Inc. (Recursion) filed its definitive proxy statement with the SEC, detailing its upcoming Annual Meeting of Stockholders to be held virtually on June 3, 2024. The proxy statement includes proposals for the election of three Class III directors, Blake Borgeson, R. Martin Chavez, and Dean Y. Li, whose terms are set to expire at the meeting. The statement also addresses executive compensation, with a recommendation for stockholders to approve the compensation of Named Executive Officers. The report highlights key achievements in 2023, such as clinical program advancements, significant partnerships, and the development of the Recursion OS platform. Additionally, the proxy statement outlines the company's executive compensation philosophy, emphasizing a pay-for-performance culture and alignment with stockholder interests. The company's financial performance, including a net loss for the year, is also discussed. The proxy statement includes information on the ownership of Recursion's common stock by certain beneficial owners and management, as well as potential payments upon termination or change in control for executive officers.
Recursion Pharmicals, Inc.（Recursion）向美国证券交易委员会提交了最终委托书，详细说明了其即将于2024年6月3日虚拟举行的年度股东大会。委托书包括选举三名三类董事的提案，即布莱克·博格森、马丁·查韦斯和李院长，他们的任期将在会议上届满。该声明还涉及高管薪酬，并建议股东批准指定执行官的薪酬。该报告重点介绍了2023年的主要成就，例如临床项目的进展、重要的合作伙伴关系以及Recursion OS平台的开发。此外，委托书概述了公司的高管薪酬理念，强调了绩效薪酬文化和与股东利益的一致性。还讨论了该公司的财务业绩，包括该年度的净亏损。委托书包括有关某些受益所有人和管理层对Recursion普通股的所有权的信息，以及执行官在解雇或控制权变更时可能支付的款项的信息。
Recursion Pharmicals, Inc.（Recursion）向美国证券交易委员会提交了最终委托书，详细说明了其即将于2024年6月3日虚拟举行的年度股东大会。委托书包括选举三名三类董事的提案，即布莱克·博格森、马丁·查韦斯和李院长，他们的任期将在会议上届满。该声明还涉及高管薪酬，并建议股东批准指定执行官的薪酬。该报告重点介绍了2023年的主要成就，例如临床项目的进展、重要的合作伙伴关系以及Recursion OS平台的开发。此外，委托书概述了公司的高管薪酬理念，强调了绩效薪酬文化和与股东利益的一致性。还讨论了该公司的财务业绩，包括该年度的净亏损。委托书包括有关某些受益所有人和管理层对Recursion普通股的所有权的信息，以及执行官在解雇或控制权变更时可能支付的款项的信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间